New Developments in Bile Acid Diarrhea

Area of Science:

• Gastroenterology
• Digestive Diseases
• Clinical Medicine

Background:

• Bile acid diarrhea (BAD) presents with severe diarrhea, urgency, and reduced quality of life, often mistaken for IBS-D or functional diarrhea.
• Pathophysiology involves accelerated colonic transit, increased mucosal permeability, and altered gut microbiome with impaired bile acid metabolism.
• Current diagnostic limitations exist, with the gold standard (48-hour fecal bile acid excretion) being cumbersome and the established test unavailable in the US.

Purpose of the Study:

• To provide an updated overview of bile acid diarrhea (BAD).
• To cover the pathophysiology, diagnostic challenges, and evolving treatment landscape of BAD.
• To highlight recent advancements in BAD diagnosis and therapeutic strategies.

Main Methods:

• Review of current literature on bile acid diarrhea (BAD) pathophysiology, diagnosis, and treatment.
• Analysis of recent clinical trial data for existing and novel BAD therapies.
• Discussion of emerging diagnostic tools and their clinical implications.

Main Results:

• Recent validation of a combined primary bile acid measurement and fasting serum marker offers a practical point-of-care diagnostic test for BAD.
• Clinical trials demonstrate the efficacy of colesevelam and liraglutide, with liraglutide showing superiority over colesevelam in one study.
• Novel therapeutic targets, including farnesoid X receptor agonists and fibroblast growth factor 19 analogs, are under investigation.

Conclusions:

• Bile acid diarrhea (BAD) is a distinct entity often misdiagnosed, necessitating improved diagnostic approaches.
• Effective pharmacological treatments are available, with ongoing research into novel agents and mechanisms.
• Advancements in diagnostics and therapeutics promise better management and improved quality of life for BAD patients.